# Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

> **NCT01038778** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Metastatic Kidney Carcinoma
- Stage III Renal Cell Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Entinostat
- **RADIATION:** Fludeoxyglucose F-18
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT01038778
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-10-29
- **Primary completion:** 2019-05-22
- **Final completion:** 2027-02-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01038778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01038778, "Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01038778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*